GLENMARK
Glenmark Pharmaceuticals Limited (GLENMARK) Stock Analysis
Glenmark Pharmaceuticals Limited is an Indian global pharma company with innovative and generic businesses. It develops dermatology, respiratory, and oncology products for India and export markets. The company has R&D and manufacturing worldwide. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹2,293.00
-1.63% 1W | +17.70% 52W
Market Cap
64.7k CR
P/E Ratio
34.6
52W High
₹2537.6
52W Low
₹1792.6
Div. Yield
0.11%
Beta
0.3
50 DMA
₹2365.9
200 DMA
₹2216.8
Profit Margin
10.1%
Inst. Own.
27.3%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating Profit | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other Income | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net Profit | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,737 |
| Expenses | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,970 | 12,410 | 12,940 |
| Operating Profit | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 4,797 |
| OPM % | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 14% | 10% | 18% | 27% | 27% |
| Other Income | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1,805 | -1,443 |
| Interest | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| Profit before tax | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,399 | 1,985 | 2,533 |
| Tax % | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 47% | 430% | 25% | 31% | |
| Net Profit | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS in Rs | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
| Dividend Payout % | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% | 10% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 14.0% | 9.0% | 8.0% |
| Profit CAGR | 61.0% | 19.0% | 12.0% |
Shareholding Pattern
Promoters46.64%
FIIs20.62%
DIIs17.64%
Public15.05%
Promoters46.64%
FIIs20.73%
DIIs18.61%
Public13.97%
Promoters46.65%
FIIs19.20%
DIIs20.09%
Public14.02%
Promoters46.65%
FIIs20.35%
DIIs19.28%
Public13.70%
Promoters46.65%
FIIs20.89%
DIIs18.60%
Public13.81%
Promoters46.65%
FIIs22.47%
DIIs10.40%
Public20.46%
Promoters46.65%
FIIs21.38%
DIIs13.36%
Public18.58%
Promoters46.65%
FIIs23.15%
DIIs14.60%
Public15.56%
Promoters46.65%
FIIs20.35%
DIIs19.28%
Public13.70%
Promoters46.65%
FIIs20.89%
DIIs18.60%
Public13.81%
GLENMARK
Holdings Analysis
Key strengths & risk signals
69
Overall
80
Fundamental
59
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.11% yield - little to no income.
RECOVERY MODE! Current price (2293.0) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -1.6% (1 week), -5.8% (1 month), 0.4% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.52 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (2365.9) is above 200-day average (2216.8) - positive signal.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
UPPER HALF! Trading at 67.2% of 52W range - positive territory.
Fundamental & Technical Analysis
69Overall
80Fundamental
59Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 13.5% (GOOD, 11/15). Profit CAGR: 66.1% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.1% profit margin - acceptable profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.52 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.11% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 18.7% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2365.9) is above 200-day average (2216.8) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (2293.0) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
6/10
POSITIVE YEAR! Stock gained 17.7% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 525,545 vs down days: 639,330. Ratio: 0.82x
RSI
3/5
NEUTRAL! RSI at 44.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 67.2% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -1.6% (1 week), -5.8% (1 month), 0.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
GLENMARK
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q3FY262026-02-04 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
| ALKEM | ₹5,279.00 | 29.3 | 14.3% | 8.3% | 32.7% | -1.9% | 68 | HIT RESISTANCE | -21.7% | +119.9% | +10.9% | +3.8% |
| ABBOTINDIA | ₹26,000.00 | 34.2 | 23.1% | 9.0% | 17.8% | -13.4% | 68 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| LUPIN | ₹1,956.50 | 16.2 | 18.5% | 19.1% | 131.5% | -1.1% | 65 | BREAKDOWN | +16.1% | -3.1% | +33.3% | +11.2% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
Data from TradeAlone · Updated daily
GLENMARK News
Glenmark Pharmaceuticals Limited Receives E Stablishment Inspection Report from U.S. FDA2026-09-23Glenmark Pharmaceuticals Limited Receives U.S. FDA Approval to Expand the Use of Ryaltris® Nasal Spray for Children Aged 6 to Less Than 12 Years2026-07-21Glenmark Pharmaceuticals Limited (glenmark) Launches Olanzapine for Injection in USA2026-07-06Glenmark Pharmaceuticals Limited Advances Multi-country Phase 3 Clinical Trial of Trastuzumab Rezetecan2026-07-02Glenmark Pharmaceuticals Limited Launches Methylene Blue Injection USP in USA2026-06-17Glenmark Pharmaceuticals Launches Winlevi® (clascoterone) 10 Mg/g Cream in Key European Markets2026-06-11Glenmark Pharmaceuticals Limited Announces New Development Candidate ISB 23012026-05-20Glenmark Pharmaceuticals Limited (glenmark) Launches Vancomycin Hydrochloride for Injection in USA2026-05-18
